Cancer Monitoring US Landscape: New Syndicated Reports
Purdie Pascoe is delighted to announce the findings from the second wave of our syndicated ctDNA Cancer Monitoring study have been published and are available to purchase.
Market situation
The use of CGP panels for cancer monitoring is increasingly becoming a key part of the treatment landscape. Physicians are exploring this new indication to determine how best to utilise it, identify suitable patients, and understand the true clinical value of minimal residual disease (MRD) and treatment response monitoring panels. A multiplication of available and upcoming products is making this market landscape extremely active and rapidly evolving.
Understanding the ctDNA landscape
Gaining a comprehensive understanding of the emerging and evolving ctDNA monitoring landscape is crucial for diagnostics companies in this space, as well as for pharmaceutical companies with product strategies linked to MRD testing. By tracking validated KPIs and market trends, your team can effectively adapt strategies and commercial plans as necessary.
Purdie Pascoe’s new syndicated study focuses on the key metrics of Cancer Monitoring Landscape in the US.
Topics include:
Awareness, Trial and Usage of ctDNA monitoring panels, including newer panels such as xM Tempus, NeXT Personalis and Haystack MRD
Sources of information
Tumour types / stages where ctDNA monitoring is used
Unmet needs, Drivers and Barriers to switch
Perceptions and behaviours toward ctDNA monitoring
Why purchase these reports?
Purdie Pascoe can support your MRD development and commercial strategy, through data and up-to-date insights coming straight from your customers.
Provide a strong, high-level overview of the ctDNA monitoring market landscape to further inform your more tailored research initiatives
Inform testing strategy relying on MRD, or how ctDNA monitoring adoption and usage might impact your overall commercial plans
Understand ctDNA monitoring adoption by practice type and tumour types
Track how this new market is evolving over the next 2 years
The wave 1 report was published in June 2024. Wave 2 results have recently been published and are available to purchase. If you are interested in both waves, our consultants would be delighted to discuss a special pricing agreement.